Alumis Inc. (ALMS)

Alumis, Inc. has experienced several significant stock events. The company's IPO took place on June 28, 2024. On January 7, 2026, the stock surged due to positive Phase 3 trial results for envudeucitinib in psoriasis, preceded by a pre-market surge on January 6, 2026. Around January 6-9, 2026, Alumis announced and closed an upsized public offering of common stock to support commercialization and pipeline development. The stock price increased by 229.44% between February 3, 2025, and January 30, 2026, and by 361.90% over the last 12 months. On November 13, 2025, Alumis reported its Q3 2025 earnings, missing the consensus estimate. An insider buying event was reported on January 13, 2026. Short interest increased in January 2026, and institutional shareholding increased in Q4 2025.

Information regarding demand seasonality for Alumis, Inc.'s products and services was not found. Demand for its products is typically driven by disease prevalence and treatment efficacy rather than seasonal fluctuations.

Alumis, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for immune-mediated diseases, utilizing a proprietary data analytics platform. The company's pipeline includes ESK-001 (envudeucitinib), an oral TYK2 inhibitor in late-stage development for psoriasis and SLE, with Phase 3 trial results for SLE expected in 2026 and Phase 3 trials for plaque psoriasis intended to be initiated in the second half of 2024. A-005, a CNS-penetrant allosteric TYK2 inhibitor, is aimed at neuroinflammatory diseases, with a Phase 1 program initiated in April 2024 and initial results expected by the end of 2024. Lonigutamab is a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for thyroid eye disease, and IRF5 is a program addressing immune dysfunction.

Alumis, Inc. is headquartered in South San Francisco, California, United States. The company's operational base is primarily in the United States, while it focuses on developing therapies with global potential.

Alumis, Inc. generally holds a positive brand reputation, particularly in the past year. The company has a "Moderate Buy" consensus rating from analysts. MarketBeat ranked Alumis higher than 85% of companies in the medical sector. The announcement of breakthrough Phase 3 trial results for envudeucitinib positively impacted its reputation.

Alumis, Inc. has a significant level of institutional ownership. As of Q4 2025, 216 institutional owners and shareholders held approximately 81.97% of the total shares, while another report from December 2025 indicated institutions held 48% ownership. Major institutional owners include AyurMaya Capital Management Company, LP, Foresite Capital Management V, LLC, Samsara BioCapital, LLC, venBio Partners LLC, Foresite Capital Management VI LLC, BlackRock, Inc., Vanguard Group Inc, Nextech Invest, Ltd., VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, and Cormorant Asset Management, LP. Hedge funds collectively own 21% of Alumis shares, with Matrix Capital Management Company, LP being the largest shareholder. Private equity firms hold a 20% stake in the company.